Drug Interaction Between Lemborexant and Lorlatinib
I cannot provide a definitive recommendation for this drug combination because the provided evidence contains no information about lemborexant (levorexant) - only extensive data about lorlatinib's interactions with other medications, particularly anticoagulants and CYP3A4 substrates.
What We Know About Lorlatinib's Interaction Profile
Lorlatinib is a moderate CYP3A4 inducer and P-gp inducer 1. Specifically:
- Lorlatinib decreased midazolam (CYP3A4 substrate) exposure by 60% in vivo 2
- Lorlatinib decreased fexofenadine (P-gp substrate) exposure by 67% 1
- Lorlatinib also inhibits BCRP in vitro 2
- The drug exhibits autoinduction, with oral clearance increasing from 11 L/h to 18 L/h at steady-state 1
Critical Missing Information
To assess the interaction between lemborexant and lorlatinib, I would need:
- Lemborexant's metabolic pathway (Is it a CYP3A4 substrate?)
- Lemborexant's transporter involvement (Is it a P-gp substrate?)
- Lemborexant's therapeutic window (How sensitive is it to exposure changes?)
Clinical Approach Based on General Principles
If lemborexant is a CYP3A4 substrate (which many sedative-hypnotics are), lorlatinib would likely decrease lemborexant exposure significantly, potentially reducing its efficacy. This would mirror lorlatinib's 64% reduction in midazolam exposure 1.
If lemborexant is a P-gp substrate, lorlatinib's P-gp induction could further reduce lemborexant bioavailability.
Practical Management Strategy
- Monitor for reduced efficacy of lemborexant (worsening insomnia)
- Consider alternative sleep medications not metabolized by CYP3A4 (e.g., trazodone, mirtazapine at low doses)
- Avoid empiric dose increases without pharmacokinetic guidance, as lorlatinib's complex effects (induction + BCRP inhibition) make predictions difficult
- Consult clinical pharmacology or use drug interaction databases with lemborexant-specific data
Important Caveat
The evidence provided focuses heavily on lorlatinib's interactions with anticoagulants in NSCLC patients 2. While this demonstrates lorlatinib's significant interaction potential, extrapolation to lemborexant requires knowing lemborexant's specific pharmacokinetic properties.